Autonomous parvoviruses possess an intrinsic oncotropism based on viral genetic elements controlling gene expression and genome replication. We constructed a hybrid vector consisting of the H1 parvovirus-derived expression cassette comprising the p4 promoter, the ns1 gene and the p38 promoter flanked by the adeno-associated viruses 2 (AAV2) inverted terminal repeats and packaged into AAV2 capsids. Gene transduction using this vector could be stimulated by coinfection with adenovirus, by irradiation or treatment with genotoxic agents, similar to standard AAV2 vectors. However, the latter were in most cases less efficient in gene transduction than the hybrid vector. With the new vector, tumor cell-selective increase in transgene expression was observed in pairs of transformed and non-transformed cells, leading to selective killing of the transformed cells after expression of a prodrug-converting enzyme. Preferential gene expression in tumor versus normal liver tissue was also observed in vivo in a syngeneic rat model. Comparative transduction of a panel of different tumor cell lines with the H1 and the H1/AAV hybrid vector showed a preference of each vector for distinct cell types, probably reflecting the dependence of the viral tropism on capsid determinants.
Introduction
A challenging problem in cytotoxic cancer therapy is to develop tumor-selective treatment strategies to avoid unintended side effects due to toxicities of the applied drug to sensitive normal cells. There are three levels at which cancer gene therapy attempts to achieve this goal: by targeting vectors to specific cell-surface receptors, by cell-type-specific gene expression and by modulation of intracellular virus/vector-host cell interactions. Liganddirected targeting of gene transfer vectors has been achieved by construction of different kinds of conjugates, providing ligands for cell attachment or by inserting short receptor ligand sequences into the vector surface structure. [1] [2] [3] A significant improvement of ligand-derived viral vector targeting has been the development of virus display libraries, allowing for the selection of ligands within the context of the vector surface structure. [4] [5] [6] [7] [8] [9] An intriguing variant of tumor targeting is the hitch hiking of vectors on T cells, which delivers them to the tumor and even to metastases. 10, 11 Furthermore, display of singlechain antibodies on virus envelope proteins also has a high potential for tumor targeting. 12 However, due to the complex pattern of cell-surface molecules on different cell types, such targeting will probably not be absolutely specific. Combination with intracellular targeting at the level of cell-type-specific gene expression will improve selectivity and specificity of gene transduction. 13, 14 Besides cell-type-specific expression cassettes, generally tumor-specific promoters also have been used such as the carcinoembryonic antigene promoter, the a-fetoprotein promoter and the mdr-1 promoter. In this context, proliferation-driven promoters such as the E2F1 promoter or the p4 promoter of autonomous parvoviruses provide another link to the properties of transformed cells. [14] [15] [16] [17] [18] The third level of tumor targeting includes cell-specific post-entry trafficking and nuclear events of vector-mediated gene transfer. In this regard, several replication competent viruses were constructed to permit replication and lysis of transformed but not of non-transformed cells. [19] [20] [21] [22] These include adenoviruses, herpes simplex viruses (HSV), reoviruses, vesicular stomatitis virus and autonomous parvoviruses.
Autonomous parvoviruses, including MVM (minute virus of mice), H1 or LuIII, are presently being explored as candidates for viro-therapy and cancer gene therapy. 18, [23] [24] [25] These viruses show antineoplastic effects, tumor-suppressive properties, an inherent oncotropism and have the capacity to lyse tumor cells. 26, 27 The intracellular oncotropism is mainly based on enhanced p4 promoter activity via binding of ATF/CreB, Ets and SP1 transcription factors in transformed cells. 28, 29 Furthermore, cell cycle-dependent activation at the G1/S transition by E2F and ATF transcription factors plays another decisive role in the observed oncotropism. 30 Expression of NS1 protein from the p4 promoter then leads to amplification of the viral genome, thereby further stimulating transformation-dependent gene expression. As NS1 also transactivates promoter p38-driven cap gene expression, virus reproduction is also strongly enhanced in tumor cells. These observations led to the idea to express foreign genes under the control of the p38 promoter to achieve a generally tumor-selective gene expression. 15, 17, 25 This expression system has so far only been analyzed and used in autonomous parvovirusderived vectors.
Gene transfer vectors derived from adeno-associated viruses (AAV) have been used for treatment of a large number of human diseases in preclinical and clinical studies. 31 This included their application in cancer gene therapy by delivering tumor suppressor genes, cytotoxic genes, drug resistance genes and genes coding for immunomodulators or antiangiogenesis factors. [31] [32] [33] In this study, we constructed a hybrid vector by introducing the autonomous parvovirus H1-derived expression cassette consisting of the p4 promoter, the NS1 gene and the p38 promoter into AAV capsids and analyzed the transduction properties of this vector in comparison to AAV2 vectors expressing transgenes under the control of the homologous AAV p5-rep-p40 expression cassette or a standard cytomegalovirus (CMV) promoter. The hybrid vector showed a superior transduction activity compared to other AAV2 vectors in HeLa cells and could become further stimulated by adenovirus, irradiation or cytotoxic agents. It showed a striking preference to transduce and kill transformed cells in vitro and also in vivo. Comparison of gene transduction of a panel of tumor cell lines by the hybrid AAV2 vector and the parental H1 vector showed that the different capsids impose cell specificity, indicating that the different vectors may complement each other for treatment of different tumors.
Materials and methods

Cell culture
Cells were maintained in Dulbecco's modified Eagle's medium or RPMI 1640 medium (Sigma, Deisenhofen, Germany) containing heat-inactivated fetal calf serum (FCS). Normal human melanocytes (NHEM) were cultured in M2 medium with supplements (PromoCell, Heidelberg, Germany). All growth media except M2 medium were supplemented with 1% penicillin/streptomycin (Sigma) and 2 mM L-glutamine (Invitrogen, Karlsruhe, Germany). Table 1 lists the different cell lines with the corresponding medium and concentration of FCS used for propagation and a reference, either published or the American Tissue Culture Collection (ATCC) or European Collection of Cell Cultures (ECACC) accession numbers.
Treatment of cells with genotoxic agents
Cells were seeded in multiwell plates with a density to show 50-75% confluency on the following day. Carmustine (BCNU), cisplatin and mitomycin C were added to the cells in concentrations as indicated in fresh cell culture medium (Dulbecco's modified Eagle's medium, 10% FCS and 1% penicillin/streptomycin). Where required, infections were performed simultaneously by addition of viral vectors into the medium. For ultraviolet (UV) irradiation, HeLa cells were seeded in six-well plates. Medium was removed and cells were washed with phosphate-buffered 
Construction of viral vectors
For construction of recombinant H1 vectors, the plasmid phH1D1600 43 was used to introduce the reporter transgenes gfp or hRluc directly into the multiple cloning site. The coding sequence for gfp was obtained from pTRUF2. 44 The codon-optimized sequence of the luciferase gene from Renilla reniformis (hRluc) was derived from phRL-TK (Promega, Mannheim, Germany).
For the construction of the rep sequence containing AAV2 vectors pP40-TK and pP40-GFP, the capsid protein-coding sequence (cap) was deleted in pTAV2 45 by HindIII-Eco105I digestion. The thymidine kinase gene from herpes simplex virus-1 (HSV-tk) was subcloned from pTK103, 46 using EcoRI-PpuMI and subsequent Klenow fill-in, into a blunted NotI site of pSL1180 (GE Healthcare, Mu¨nchen, Germany). In the resulting plasmid pSLTK, the multiple cloning site was partially deleted by BclI-NdeI digestion, subsequent Klenow fill-in and religation (pSLTK-LCS) to keep the final vector genome as short as possible. A semiblunted (sb) SalI-HindIII HSV-tk fragment from pSLTK-LCS was ligated with an Eco105I-HindIII-digested pTAV2 plasmid fragment, resulting in pTRTK. The rep coding region from pTAV2 (HindIII fragment) was reintroduced into the HindIII site of pTRTK, giving rise to the AAV vector plasmid pP40-TK. To exchange gfp against HSV-tk gene, pP40-TK was digested with XhoI-BamHI, which leads to the generation of three fragments. A BamHI-BglII gfp fragment isolated from pTRH1-GFP (described below) was first ligated with the backbone fragment (pTRGFP), and the rep coding sequence was reintroduced therein using the XhoI site to build up the vector plasmid pP40-GFP.
For generation of hybrid vector plasmids, the sequence containing the P4 promotor, ns1 gene, the p38 promotor and a polyadenylation sequence from H1 virus was subcloned. To this end, phH1D1600 was digested with BssHII (sb)-NdeI and the internal parvovirus fragment cloned into semiblunted NotI-NdeI-digested pSL1180. The resulting plasmid pSLH1 was deleted in one polyadenylation sequence by BamHI digestion and religation to generate pSLH1DpA. Digestion of this plasmid with NruI-SalI releases the P4-ns1-P38 sequence. pTRUF2 was used to supply the terminal repeats (TRs) to the AAV2 hybrid vectors. EcoRI-SalI digestion deletes all coding sequences from pTRUF2, having a residual fragment whose blunted EcoRI site was ligated with the P4-ns1-P38 sequence prepared as described above. The resulting plasmid pTRH1 contained the AAV2 TRs flanking the P4-ns1-P38 sequence. Excision of gfp from pTRUF2 and insertion into pTRH1 using NotI resulted in hybrid vector plasmid pTRH1-GFP. To construct a HSV-tk-expressing hybrid vector, the polyadenylation sequence from pTRH1 was deleted through SphI and SalI digestion followed by end blunting using both, Klenow and T4 DNA polymerases. This plasmid (pTRH1DpA) was supplemented with the HSV-tk sequence using XhoI-BamHI restriction sites. The HSV-tk sequence was obtained from XhoI-BamHI-digested pSLTK-LCS (see above). To construct a luciferase-expressing hybrid vector, the luciferase gene hRluc was excised from phRL-TK using NheI and NotI restriction sites. After end blunting, this fragment was ligated with plasmid pTRH1-GFP from which gfp had been removed by digestion with XhoI and NotI. This resulted in hybrid vector plasmid pTRH1-hRluc. pTRUF2 44 is an AAV2 vector plasmid encoding the gfp sequence under control of CMV immediate-early promotor/enhancer. To generate pCMV-TK, the gfp gene was deleted from pTRUF2 by BamHI digestion and blunting of the ends, and the HSV-tk sequence from pSLTK-LCS was inserted as a blunted SalI-BamHI fragment. In pCMV-hRluc, the luciferase gene originated from a NheI (sb)-NotI fragment from phRL-TK, which was ligated with XbaI (sb)-NotI-digested plasmid pCMV-TK, whereby HSV-tk was replaced by hRluc.
Vector production and quantitation Recombinant AAV particles were generated by calcium phosphate co-transfection essentially as described. 47 293T cells (4 Â 10 6 ) were seeded into each 15 cm dish and cotransfected on the following day with 54 mg of packaging plasmid pDP2 48 and 18 mg of the particular AAV2 vector plasmid. A mixture containing the plasmid DNAs, 625 ml of 2.5 M CaCl 2 and H 2 O (ad 6.25 ml) for five concomitant transfections was prepared and mixed with 6.25 ml 2 Â Hank's buffered salt solution under continuous gentle vortexing. The mixture was incubated without shaking for 90 s to allow complex formation. The transfection mixture was then added to pre-warmed cell culture medium (20 ml per dish). Supernatant from the cell culture was changed against fresh medium containing the transfection mixture. After 48 h incubation, the supernatant was discarded, cells were harvested by scraping and resuspended in 2 ml of sterile PBS-MK (PBS, 2.5 mM MgCl 2 , 1 mM KCl, pH 7.2) per dish. Recombinant H1 particles were also produced by co-transfection of vector and packaging plasmids into 293T cells using the calcium phosphate transfection method. As a packaging plasmid, pCMV-VP 43 was used. A 48 mg portion of packaging plasmid was co-transfected with 24 mg of the respective vector plasmid. After 48 h, the cell suspension was frozen and thawed at À80 and 37 1C, respectively, for lysis. A 100 U portion of benzonase per ml (Sigma) was added and incubated with the lysate at 37 1C for 30 min. Cellular lysis was continued with two further freeze-thaw cycles. Viral vectors were purified as described 49 by centrifugation with iodixanol (OptiPrep Sigma). Viral vectors were collected with a syringe within a 4 ml fraction. Viral vectors were dialysed against PBS-MK and concentrated at the same time using VivaSpin20 concentrators (10.000 MWCO; Sartorius AG, Goettingen, Germany) to a desired volume of 1-2 ml.
Recombinant AAV vectors were quantified by replicative Dot Blot titration 50 giving infectious titers expressed as replicating units (r.u.). Instead of HeLa cells, HeLaRC cells expressing Rep and Cap proteins 35 were used. Recombinant H1 vectors were quantified by an infected cell hybridization assay as described 51 and are similarly expressed as replicating units.
Both, for rAAV and rH1 vectors, determination of genome-containing particles was performed as described. 50 For hybridization, the respective transgene sequences of the vectors, that is, gfp, HSV-tk or hRluc was used as probes. Western blot analysis A 10 mg portion of total proteins was fractionated by polyacrylamide gel electrophoresis in presence of sodium dodecyl sulphate (SDS-polyacrylamide gel electrophoresis) and electroblotted onto a nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany) and incubated with 5% fat-free milk in PBS with 0.05% Tween 20. For immunodetection, monoclonal anti-GFP antibodies (Roche, Mannheim, Germany) were used as primary antibodies followed by peroxidase-conjugated goatanti-mouse (Dianova, Hamburg, Germany) as secondary antibodies. Chemoluminescence reaction was carried out with the Western Lightning kit (PerkinElmer, Ju¨gesheim, Germany).
Determination of transduction by Fluorescenceactivated cell sorting analysis
Flow cytometry was performed to detect gfp reporter gene expression after infection of cells with different recombinant viral vectors. Cells were infected at indicated MOI and harvested 48 h after infection by trypsinization. Cells were washed and resuspended in 0.5 ml of sterile filtered PBS. Fluorescence-activated cell sorting analysis was carried out using a FACScan (Becton Dickinson, Heidelberg, Germany) equipped with a 488 nm argon laser. Data from 10 000 cells per sample were collected and results analyzed in a histogram plot using CellQuest software.
Cell-killing assay Cells (2.5 Â 10 3 ) per well were seeded in 96-well plates and infected the next day. Two days after infection, ganciclovir (GCV) (Cymevene; Roche) was added at concentrations ranging from 0 to 1000 mM within 100 ml of fresh cell culture medium. Cells were incubated with GCV for 5 days before 100 mg of the tetrazolium salt 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromid (MTT; Sigma) was added to each well. MTT was kept on cells for 4 h in the dark under cell culture conditions. In intact mitochondria, MTT is converted into violet formazane, which forms precipitates. After incubation, the supernatants were removed carefully and dimethylsulfoxide was added to the 96-well plates (100-200 ml per well), which were closed with a parafilm-sealed lid and kept for 60 min to dissolve the precipitates. Optical densities of the samples were determined at 540 nm. Non-infected and non-GCV-treated cells were set to 100% viability. The GCV-dependent loss of viability of infected cells was taken as a measure of HSV-TK gene transduction efficiency, after subtraction of the nonspecific effect of GCV.
Determination of transgene expression in normal rat liver tissue versus Morris hepatoma malignancies
After premedication with 50 mg ketamine (Ketanest; Berlin, Germany) per kg body weight and 0.5 mg N-(3 0 -dimethylamino-propyl)-3-propionyl-phenothiazine-phosphate (Combelen; Bayer, Leverkusen, Germany), ACI rats (200-250 g) were kept in an inhalation narcosis with enflurane (0.4 volume %), nitrous oxide (flow ¼ 1000 ml min
À1
) and oxygen (flow ¼ 500 ml min
). MH3924A cells (1 Â 10 6 in a volume of 100 ml in PBS) were directly injected with a 27-gauge needle into one lobe A of the rat liver. Cuts were sewed with absorbable Safil. Within 10 days, a tumor developed in the rat's livers. Animals were anesthetized as before, and each 1 Â 10 11 genomic vector particles were injected into the tumor and into liver tissue of the same animal, preferably into lobe C if applicable. Three days after infection with rH1 vector and 15 days after infection with rAAV2 vector, animals were killed and the livers were removed. Livers were dissected from the tumors and separately cut into tissue samples of 200 or 50 mg, respectively. Each sample was lysed in 1 ml of Renilla Lysis Buffer (Promega) using an Ultra Turrax homogenizer. Lysed tissue samples were applied for protein quantification using the Nano Orange Protein Quantitation kit (Invitrogen). Lysed tissue samples were quantified in 1/500, 1/1000 and 1/2000 dilutions in duplicates against a reference with bovine serum albumin in a fluorometer at 485 nm/535 nm (extinction/emission). Luciferase expression was quantified with Renilla Luciferase Assay System kit (Promega). Tissue sample (20 ml) were mixed with 100 ml assay mix and measured for 10 s in a luminometer (Lumat; Berthold Technologies, Bad Herrenalb, Germany). Light units were then normalized with the amount of total protein.
Statistics
Data were analyzed according to the unpaired two-tailed Student's t-test and considered significant for P-values less than 0.05. Results are shown as means ± s.d.
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Results
Organization of parvoviral vectors
The parvoviral hybrid vector TRH1 ( Figure 1a ) has been constructed to combine features of the well-established AAV vector system with oncotropic gene expression characteristics of the autonomous parvovirus H1. In this vector, a given transgene-green fluorescence protein (gfp), thymidine kinase (tk) or humanized luciferase from R. reniformis (hRluc)-is controlled by the H1 p38 promoter. This promoter is transactivated by the H1 NS1 protein expressed from the P4 promoter, which contains regulatory cis-acting DNA elements stimulating gene expression in proliferating and transformed cells. 15, 18, 29, 30, 52, 53 The whole expression cassette is flanked by AAV2 inverted terminal repeats (ITRs) required for packaging into AAV2 capsids. A detailed diagram of the AAV-H1 junction is shown in Figure 1e . The complete AAV2 terminal repeat with the Rep binding site (RBE), the terminal resolution site (trs) and D-sequence is conserved. Owing to cutting the H1 left terminal palindrome in the middle between the rabbit ear structure with BssHII, the H1 portion retains the cAMPresponse element binding site a (CREa), the USF binding site (E-box) overlapping with the binding site for NF-Y (Y-Box), the binding sites for E2F (E2F-bs), Ets (EBS) and SP1 (G-box) in front of the TATA element and the transcriptional start site (tss). Binding sites for parvovirus promoters. Transcription of a transgene (gfp or HSV-tk) is driven by the P40 promoter. (d) TRUF is a bicistronic recombinant AAV2 vector expressing GFP and neomycin-phosphotransferase driven by the viral promoters from cytomegalovirus (P CMV ) and HSV (P TK ). 44 In the CMV-TK and CMV-hRluc derivatives, gfp has been replaced by the HSV-tk suicide gene or the humanized luciferase sequence from R. reniformis (hRluc). Transcripts from vectors shown in Panels a-c are terminated at a single polyadenylation signal (black box), while the TRUF vectors and its derivatives contain two separate polyadenylation signals. (e) Details of the left end AAV2-H1 junction of TRH1 vectors indicate the rep binding site (RBE), the terminal resolution site (trs) and the D-sequence of the AAV2 TR, the PIF binding site (PIF-BS) and the NS1 binding site (NS1-BS), the cAMP-response element a (CREa), E-box overlapping with the Y-box, binding sites for E2F (E2F-bs), Ets (EBS) and SP1 (G-box) transcription factors in front of the TATA-box and the p4 promoter transcription start site (tss). HSV, Herpes simplex virus.
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L Krüger et al initiation factor and NS1 are indicated. To evaluate the characteristics of this vector, we compared it to the corresponding parental vectors, for example, the H1 vector or vectors derived from AAV2. The parental H1-derived vector (Figure 1b) contains the same p4-ns1-p38 expression cassette as the hybrid vector, however, in this case flanked by the H1 TP enabling the packaging into H1 viral particles. The H1 vector used in this study was deleted of 1600 nucleotides in its capsid gene sequence compared to H1 virus. 43 The corresponding AAV2-derived vector (Figure 1c) contains an AAV2 expression cassette consisting of the AAV2 p5 promoter expressing the Rep proteins (Rep78 and Rep68) and the P40 promoter, which controls expression of the transgens. The P19 promoter located between the p5 and p40 promoters, in the open reading frames of Rep78 and Rep68 expresses the Rep proteins Rep52 and Rep40. These proteins have no transactivation activity, whereas Rep78 and Rep68 repress the p5 promoter and transactivate the p40 promoter to some extent when the TRs are present. [54] [55] [56] This vector is packaged into AAV2 capsids via the AAV2 TRs. Finally, an AAV standard vector (TRUF, Figure 1d ) with AAV2 TRs but without any viral genes expressed the transgens (for example, gfp, tk or hRluc) under the control of the human CMV promoter. In addition, a neomycin phosphotransferase gene (neo r ) is driven by the thymidine kinase promoter (Ptk from HSV). The poly-A signals of the different vectors are identical and are derived from bovine growth hormone. 44 The gfp sequence from pTRUF2 has been introduced into all of the GFP-expressing vectors to allow a quantitative comparison.
TRH1-GFP achieves improved transduction of HeLa cells in absence of adenovirus
To characterize the transduction efficiency of hybrid vector TRH1 in comparison to the two other AAV2 vectors (P40GFP and pTRUF), HeLa cells were infected with the different vectors of MOIs of 10, 50 and 100 r.u. per cell, either in absence or in presence of Ad5 (Figure 2 ). Cells were harvested 3 days after infection, and gene transduction was quantified by FACS analysis. In absence of adenovirus coinfection, the hybrid vector showed about fourfold increased transduction of HeLa cells compared to the standard vector TRUF. As expected, the P40 vector showed the lowest transduction because the p5 and p40 promoters are largely inactive in HeLa cells in presence of Rep proteins and in absence of adenovirus. 35, [57] [58] [59] Coinfection with Ad5 augmented transduction with all AAV2 vectors, which was most pronounced with the P40 vector. This is most likely due to transcriptional stimulation of p5 and p40 promoters by Ad5 and to the increased intracellular processing, including single-strand conversion. [60] [61] [62] In addition, Southern blot analysis of transduced DNA showed that p40-GFP DNA was strongly amplified by adenovirus coinfection leading to an increase in templates for gene expression (Figure 2b) . Stimulation of gene transduction by adenovirus was also observed with TRUF and the hybrid vector TRH1-GFP.
There was also an improvement of single-to doublestrand conversion of TRH1 observed in presence of adenovirus. However, no efficient DNA amplification was detected, as it was the case for the P40-GFP vector (Figure 2b ). This is consistent with the fact that the hybrid vector only retains the inactive form of the H1 origin of replication. At the highest MOI (MOI 100), the stimulation of gene expression with Ad5 was not any more evident. This was possibly due to complementary strand annealing at high MOIs, which circumvents the need for adenovirus stimulated second strand synthesis. Enhanced transduction with hybrid vector TRH1-GFP is due to stronger promoter activity To exclude vector-specific effects including uncoating and single-strand (ss) to double-strand (ds) conversion, we compared GFP expression in 293T cells after transient transfection of vector plasmids pP40-GFP, pTRUF, pTRH1-GFP and phH1-GFP by FACS analysis (Figure 3a) . The fluorogram shows a superior gene expression from the pTRH1 vector compared to either pP40-GFP, pTRUF2 or phH1-GFP. This difference is mainly based on GFP expression per cell, because comparable numbers of GFP-positive cells were counted after transfection of the different plasmids. Also western blotting confirmed the approximately 10-fold improved gene expression with the hybrid vector plasmid. The observation that transfection of vector plasmid phH1-GFP resulted in lower gene transduction than transfection of pTRH1-GFP was unexpected, since both plasmids contain the same P4-ns1-P38 expression cassette. The main difference between the two plasmids is the potential of phH1-GFP to excise and autonomously amplify the H1 sequence. This might lead to a premature cell death of those cells due to the known cytotoxicity of NS1 when it is over expressed.
63-66
Irradiation or treatment with cytostatic drugs at the time of infection augments HeLa cell transduction with all AAV vectors Besides adenovirus coinfection, irradiation of cells or treatment with cytostatic drugs stimulates transduction with AAV2 vectors. [67] [68] [69] [70] [71] [72] Therefore, the influence of g-irradiation or UV irradiation on transduction of HeLa cells with TRH1-GFP in comparison to P40-GFP and TRUF was examined. Half-lethal irradiation doses of 50 Gy or 25 J m À2 , respectively, had been determined by MTT assay of the cells 48 h after irradiation exposure. HeLa cells were irradiated directly before infection with AAV2 vectors (MOI 10). While infection of nonirradiated cells resulted in only a very low number of GFP-expressing cells at this MOI, there was significant stimulation of transduction with all AAV2 vectors after irradiation (Figure 4a) . Stimulation of transduction with X-rays was stronger than with UV irradiation (Figures 4a versus b) . Under comparable conditions, a four-to fivefold stimulation of transduction with a standard AAV2 vector was reported after exposure of fibroblasts to UV light. 73 Also the impact of treatment with cytostatic drugs, mitomycin, cisplatin and BCNU (Carmustine) on transduction of HeLa cells with different AAV2 vectors was compared (Figures 4c and d) . Cells were treated with BCNU at a concentration of 20 mM and with mitomycin and cisplatin at concentrations of 250 ng ml À1 and 1 mg ml À1 , respectively. Treatments with each of the cytostatic drugs resulted in a stimulation of transduction with P40-GFP and TRUF vectors comparable to that after X-ray irradiation. However, while cisplatin and BCNU also stimulated transduction with the hybrid vector (TRH1-GFP), transduction was not enhanced in presence of mitomycin (Figure 4d ). In conclusion, gene transduction into HeLa cells using the hybrid vector TFH1-GFP could be stimulated by coinfection with adenovirus or treatment with genotoxic agents (with the exception of mitomycin), similarly to the AAV2 P40 vector or the TRUF standard vector. This suggests that the same steps of uncoating and singlestrand to double-strand conversion limit transduction mediated by the hybrid vector as compared with in the two AAV2 reference vectors. However, the hybrid vector allowed overall a higher number of cells to be transduced after each treatment. We also analyzed gene transduction of HeLa cells in presence and absence of genotoxic agents or adenovirus using the H1 vector (Figure 4e) . With all treatments, a significant stimulation of gene transduction was noted, although the stimulation was relatively weak, possibly because transduction was already high in absence of any additional treatment.
Transformation-selective transduction of cells with the hybrid vector TRH1
To explore the possible stimulating effect of transformation on gene expression driven by the hybrid vector, we analyzed gene transduction of three matched pairs of transformed and non-transformed cells by the three AAV2 vectors P40-GFP, TRUF5 and TRH1-GFP (Figures 5a, b and d) . In addition, we compared gene HaCat are spontaneously immortalized keratinocytes, from which HaCat T30ras clone was generated through additional transformation with the ras oncogene. Normal human epithelial melanocytes are primary non-transformed cells, and were compared to the Bowes melanoma However, to our surprise this was also the case with the P40 and TRUF5 vectors, although their levels of induction were lower in comparison with hybrid TRH1. Therefore, the difference between AAV references and hybrid vectors lay both in the relatively higher responsiveness to host cell transformation and a much higher capacity for transgene expression achieved by the latter vector.
To test whether this preferential gene expression in transformed cells can be translated into selective killing of the transformed cells, we used vectors expressing the HSV-tk suicide gene instead of gfp. Addition of the prodrug GCV to HSV-tk-expressing cells kills those cells and also neighboring cells by means of a bystander effect. 74 Figure 6 compares the survival of the indicated cell pairs VH10/VH10SV40 (Figure 6a In two independent experiments, we failed to detect any selective or preferential vector entry into transformed cells (data not shown). This clearly shows that the oncoselectivity of the vectors occurs not at the level of vector cell entry. The CMV-driven expression of tk was initially intended to serve as a control for the non-oncotropic expression of the suicide gene. However, as apparent from the GFP expression data shown above ( Figure 5 ), also the CMV-driven expression cassettes proved to be endowed with some selectivity for transformed cells in the AAV context, in keeping with the preferential CMV-TK vector-mediated killing of the cells.
Preferential gene expression in tumors in vivo
To investigate gene expression in normal versus tumor tissue in vivo, rats were injected with 10 6 Morris hepatoma cells (MH3924A) into one lobe (A) of the liver. Within 10 days, a solid tumor developed, which was then injected with 10 11 genome-containing particles. In addition, the same amount of vector was injected into a non-tumorbearing lobe (B or C) of the liver. The humanized luciferase gene from R. reniformis (hRluc) was chosen as a reporter and expressed using vectors CMV-hRluc (CMVdriven expression; AAV capsid), TRH1-hRluc (P4-ns1-P38-driven expression; AAV2 capsid) or rH1-hRluc (P4-ns1-P38-driven expression, H1 capsid). Expression of recombinant H1 vector peaked at 3 days post-infection, while expression driven by AAV2 vectors slightly increased further until it reached a plateau between 10 and 15 days post-infection (data not shown). For preparation of extracts, tumors and normal liver tissues were separately excised, weighted and cut into pieces of similar weight. In Figure 7b Augmented transgene expression in transformed cells L Krüger et al transduction levels were achieved in vivo by the H1-based vector. Similarly, rH1-hRluc was more efficient than the AAV-based vectors CMV-hRluc and TRH1-hRluc in transducing hepatoma cells in vitro (Figure 7a ), in keeping with the higher permissiveness of these cells for a vector that is derived from a rat parvovirus. Interestingly, the CMV-driven AAV2 vector showed slightly higher gene expression in the rat hepatoma cells than the hybrid vector TRH1, indicating that the strength of the different promoters is also cell-type dependent. With respect to the tumor selectivity of gene expression, the H1-derived vector showed the lowest degree of oncotropism (hepatoma versus normal liver parenchyma) in this in vivo context (Figure 7b ).
The parvoviral vectors TRH1-GFP and rH1-GFP transduce different human tumor cells with different efficiencies Owing to their different flanking terminal palindromes, vector plasmids TRH1-GFP and rH1-GFP became packaged into AAV (TRH1) and H1 (rH1) capsids, respectively. Thus, the two viral vectors containing the same expression cassette should transduce different tumor cells with different efficiencies according to the respective receptors they use for cell infection. While AAV2 capsids are known to bind heparansulfate proteoglycan and use aVb5 integrin, FGFR1, HGFR1 or laminin as (co)receptors, the autonomous parvovirus H1 is only known to depend on cellular sialic acid for binding. [75] [76] [77] [78] [79] [80] A panel of human tumor cell lines was used to compare the two vectors for their transduction efficiencies (Figure 8 ). These cell lines originate from various tumors: rhabdomyosarcoma (A204), adenocarcinoma of the lung (Calu-6), prostate (DU-145; PC3) and mammary (MCF-7; MDA-MB) carcinomas, neuroglioma (H4), neuroblastoma (SK-N-MC), medulloblastoma (TE 671), glioblastoma (U-87MG) and cervical carcinoma (HeLa). The latter cells were known to be permissive for transduction with both vectors. Striking differences were observed between both vectors in their respective transduction capacities, depending on the target tumor cells: rH1-GFP was superior to TRH1-GFP in prostatic (DU-145; PC3) and cervical (HeLa) carcinoma cells, whereas TRH1-GFP was more efficient than rH1-GFP in tumor cells from the nervous system (H4, SK-N-MC, TE 671 and U-87MG). The efficacy of transduction was similar for both vectors MDA-MB). It was considered from these results that the origin of the capsid (AAV2 versus H1) strongly impacts on the competence of the vector for transducing distinct cell types. Hence, both members of parvoviruses offer complementing advantages regarding their ability to target human tumor cells.
Discussion
The use of AAV vectors as a gene delivery agent in cancer therapy is showing promise in preclinical studies. [31] [32] [33] 81 The aim of this study was to test the properties of a hybrid vector consisting of the p4-ns1-p38 expression cassette derived from the autonomous parvovirus H1 incorporated into the AAV capsid, thanks to its flanking with AAV ITRs. Gene expression using this cassette has been shown to be enhanced in transformed cells compared to non-transformed cells, thereby providing a generally increased transgene expression in various transformed and tumor cells. 15, 17, 25 We asked specifically whether the transformation-dependent targeting of gene expression was maintained in the new vector background and whether this also holds true for in vivo gene expression. We observed strongly increased gene transduction in transformed cells versus non-transformed cells using the hybrid vector and observed this also in vivo. However, the data show that the previously proposed explanation for this phenomenon-namely that the transformation-and proliferation-dependent upregulation of gene expression is caused by the autonomous parvovirus p4 promoteronly accounts for part of this phenomenon because other promoters tested in parallel in the AAV2 vector showed the similar transformation-specific increase in gene transduction.
Gene transduction efficiency of AAV vectors depends on cell entry and several post-entry steps, including intracellular trafficking and uncoating, the formation of double-stranded genomes (single-strand-conversion) and finally the promoter activity. Comparison of gene transduction with AAV2 vectors harboring either the parvovirus-derived promoters (hybrid vector) or the homologous AAV2 promoters (p40-GFP) or a standard CMV promoter (TRUF) showed higher gene transduction of the hybrid vector in HeLa cells. Because the three expression constructs were packaged into the same AAV2 capsids, the observed differences in gene transduction should not be due to cellular uptake and post-entry trafficking but rather to differences in single-strand conversion or promoter activities. The transfection experiments, which circumvented the single-strand conversion step, showed significant differences in promoter strength in HeLa cells with the highest expression from the p4-ns1-p38 expression cassette, a lower expression from the CMV promoter and the lowest expression from the AAV p5-rep-p40 expression cassette. However, this ranking may change in other cell types as seen, for example, in the Morris hepatoma cells.
It is well known that gene transduction with AAV2 vectors can be stimulated by coinfection with adenovirus, by irradiation or by treatment with compounds exerting a genotoxic stress to the cells. [70] [71] [72] Each of these stimuli also augmented gene transduction with the hybrid vector to an extent comparable with that of the two other tested vectors (p40-GFP and TRUF), with the exception of mitomycin. It should be stated that in this experiment, transduction of HeLa cells with the hybrid vector in absence of mitomycin was unexpectedly high, which might have masked the stimulating effect of any drug. These treatments are thought to stimulate intracellular trafficking 62 and/or the conversion of the incoming singlestranded genome into a double strand (single-strand conversion). 60, 61, [82] [83] [84] [85] The mechanisms for single-strand conversion for AAV and autonomous parvovirus genomes may be different. 86 Because in the hybrid vector the ss-conversion cannot be primed from the H1 left end terminal palindrome sequence, the single-strand conversion should follow the AAV characteristics. This was confirmed by the strong stimulation of gene transduction and expression by adenovirus coinfection as well as by generation of genotoxic stress using irradiation or chemical treatments. It has also been reported that AAV is able to sensitize tumor cells to cisplatin, etopoxid or doxorubicin, and reduces the site effects of 5-fluoro uracil. [87] [88] [89] These properties of AAV together with the increased gene transduction rate in presence of these drugs may potentiate AAV's efficiency as an antitumor vector system.
The basis of oncoselectivity of autonomous parvoviruses MVM and H1 is their preferred replication in proliferating cells, 90 the enhanced cytotoxicity in transformed cells [64] [65] [66] 91 and the increased p4 promoter activity in proliferating and transformed cells. 18 The hybrid vector analyzed here, with part of the H1 left end terminal palindrome, the p4 promoter and the ns1 gene is not replication competent (Figure 2b) . Thus, this aspect of oncoselectivity is lacking in this vector. Nevertheless, reporter gene activity and suicide gene action of the hybrid vector in transformed and non-transformed cell pairs was very similar to the one reported for the MVM vector analyzed by Dupont et al. 15 There remains the p4 promoter activity to explain the oncoselective gene transduction. To analyze the specific contribution of the p4 promoter for transformation-selective gene expression, we included in our analysis the p5-rep-p40 expression cassette derived from AAV2 and the constitutively active CMV promoter/enhancer. Surprisingly, these two expression systems showed similar cell transformation-selective increase in gene expression as the hybrid vector, although at a different expression level. This result suggests that not only the parvoviral p4 promoter in the hybrid vector selects for the augmented gene expression in transformed cells. Since both, the CMV promoter-driven and p5-rep-p40-containing vectors do not contain ns1, the influence of NS1 on transformed versus non-transformed cells can also not dictate the striking selectivity of gene expression. Because virus uptake is also not different in transformed and non-transformed cells, (a) post-entry step(s) in gene transduction seem to be most likely responsible for the observed differences in gene transduction between transformed and non-transformed cells. On the basis of the presented data, one cannot discriminate between postentry trafficking, nuclear uncoating and/or ss-conversion. All three processes have been reported to influence gene transduction using AAV vectors. [92] [93] [94] This type of intracellular tumor targeting was also observed in vivo. The tumor model chosen allowed the transduction efficiency and selectivity of the hybrid vector to be compared with those of the CMV promoter-containing AAV vector and the authentic H1 vector. Although transduction of the rat tissue with AAV-based vectors was less efficient than with the H1-based vectors-as expected from in vitro data-the selectively enhanced expression in the tumor tissue compared to normal liver was similar with each of the vectors applied. This means that in vivo post-entry trafficking and/or ss-conversion may also play a dominant role for the observed selective gene expression. This is especially evident from the higher difference in gene transduction between tumor and normal liver tissue obtained with the CMV promoter-containing vector compared to the hybrid vector or the H1 vector. The relatively high level of gene expression of the H1 vector in normal liver tissue was unexpected, as single-strand conversion of autonomous parvovirus vectors was proposed to depend on cell proliferation, which is not the case in the majority of liver cells. 86, 95 However, histological analysis would be required to determine the cell type in the liver tissue, which has been transduced by the H1 vector. Moreover, the expression kinetics revealed accelerated gene expression of the H1 vector compared to the AAV vectors, showing an approximately 100-fold higher gene expression at day 3 after vector application compared to the differences of activity measured at day 15 (data not shown). In contrast to this, the transduction activities of the AAV vectors slowly increased until it reached a plateau between 10 and 15 days post-application. This indicates accelerated uncoating and ds-formation for the H1 vector.
The comparison of gene transduction of a panel of different tumor cell lines by the AAV and H1 vectors indicated that they have distinct spectra of target cells due to the different receptors used for cell entry. 75, [77] [78] [79] [80] Thus, the two vector systems are complementary to each other regarding the spectrum of tumor cells to which they can be applied. The suitability of each of these vector systems for anticancer applications may also differ depending on the type of transgene to be expressed. Indeed, the AAVand H1-based vectors were found to differ markedly in their expression profiles irrespective of the promoters involved and of the coexpression of any viral proteins. H1 vectors provide a rather strong, however, transient gene expression, whereas AAV vectors show a slowly increasing long-term gene expression profile. Moreover, gene amplification within the cell transduced with the H1 vector provides the ability to further increase gene expression in transformed cells. In contrast, the versatility of the AAV-based vector system has been expanded in the past years by the discovery of different AAV serotypes with different cell and tissue tropisms. 96, 97 Cross-packaging of the same vector DNA into capsids of different serotypes is a valuable approach to test for preferred tropisms, which can further be modified by mosaic formation. 98 In addition, vector targeting by genetic modification of the AAV2 capsid 1,2 construction of chimeric vectors and the development of combinatorial AAV vector libraries 4, 8, 9, 99, 100 further increases the potential of this vector family. An obvious future goal will be to combine surface targeting with the here described expression targeting to achieve an optimum of specificity and efficiency of gene transfer using AAV vectors.
